Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases

被引:0
作者
Koji Habe
Hideo Wada
Takeshi Matsumoto
Kohshi Ohishi
Makoto Ikejiri
Kimiko Matsubara
Tatsuhiko Morioka
Yuki Kamimoto
Tomoaki Ikeda
Naoyuki Katayama
Tsutomu Nobori
Hitoshi Mizutani
机构
[1] Mie University Graduate School of Medicine,Department of Dermatology
[2] Mie University Graduate School of Medicine,Department of Molecular and Laboratory Medicine
[3] Mie University Graduate School of Medicine,Department of Blood Transfusion
[4] Mie University Graduate School of Medicine,Department of Obstetrics and Gynecology
[5] Mie University Graduate School of Medicine,Department of Hematology and Oncology
来源
International Journal of Hematology | 2013年 / 97卷
关键词
APS; Thrombosis; aPL; LA; β2-Glycoprotein I;
D O I
暂无
中图分类号
学科分类号
摘要
Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.
引用
收藏
页码:345 / 350
页数:5
相关论文
共 130 条
  • [1] Palomo IG(2007)An insight into the pathophysiology of thrombosis in antiphospholipid syndrome Front Biosci 12 3093-3103
  • [2] Segovia FM(2012)Anti-phosphatidyl- ethanolamine antibody, thromboembolic events and the antiphospholipid syndrome Autoimmun. Rev. 52 804-10
  • [3] Alarcon ML(2010)Antiphospholipid syndrome and the brain in pediatric and adult patients Lupus 19 406-411
  • [4] Fuentes BY(2007)Hughes Syndrome: the antiphospholipid syndrome–a clinical overview Clin Rev Allergy Immunol 32 3-12
  • [5] Pereira JG(2001)Management of thrombosis in women with antiphospholipid syndrome Clin Obstet Gynecol 44 36-47
  • [6] Rojas A(2000)Protein C Activity in patients with antiphospholipid syndrome J Clin Rheumatol. 6 239-243
  • [7] Forastiero R(2010)Complement activation on platelets: implications for vascular inflammation and thrombosis Mol Immunol 47 2170-2175
  • [8] Staub HL(2010)Impaired fibrinolysis in the antiphospholipid syndrome Curr Rheumatol Rep 12 53-57
  • [9] Bertolaccini ML(2012)The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity Semin Arthritis Rheum 42 66-69
  • [10] Munther MA(2010)Antiphospholipid syndrome Lancet 376 1498-1509